EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparing dual oral agents plus insulin vs. Triple oral agents in uncontrolled type II diabetes: A pilot study

Nadia Gul, Inayat Ur Rehman iD, Yasar Shah iD, Arbab Muhammad Ali, Zahid Ali, Omer Shehzad, Khang Wen Goh, Long Chiau Ming, Amal K Suleiman

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0311435 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Nadia Gul und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Garden Campus, Abdul Wali Khan University Mardan, Mardan, Pakistan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin, Metformin, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Type II Diabetes mellitus (T2DM) patients often do not achieve glycemic control with oral hypoglycemic agents (OHAs). There are two main approaches to address this challenge: transitioning to a triple OHA regimen, or adding Insulin to the existing dual OHA regimen.

Aim

This study aimed to compare the efficacy of adding Insulin to dual OHAs (Sitagliptin + Metformin) against adding a third OHA to Sitagliptin + Metformin in achieving glycemic control among patients with uncontrolled T2DM.

Method

A pre-post study was conducted between 21 September 2023 and 21 December 2023 at Services Hospital Peshawar, Pakistan. Patients with uncontrolled T2DM with >7% HbA1c were divided into group 1 (Sitagliptin + Metformin plus a third OHA), and group 2 (Sitagliptin + Metformin plus pre-mixed Insulin 70/30). Glycemic control based on HbA1c values, fasting and random blood sugar levels, lipid profile, and body weight were evaluated after 3 months of therapy. The pre- and post- effect was compared by using a paired t-test.

Results

The study included n = 80 patients with T2DM. Between groups 1 and 2, no significant difference was found in HbA1c values (9.1 vs. 9, with p = 0.724). However, BMI, cholesterol, and LDL significantly decreased in group 1 compared to group 2 (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2InsulinMetforminHypoglycemic AgentsSitagliptin PhosphateDrug Therapy, CombinationGlycated HemoglobinHumansMaleFemaleMiddle AgedPilot ProjectsAdministration, OralBlood GlucoseAdultAgedGlycemic Control

Substanzen

InsulinMetforminHypoglycemic AgentsSitagliptin PhosphateGlycated HemoglobinBlood Glucose

Autor:innen und Institutionen

  • Department of Pharmacy, Garden Campus, Abdul Wali Khan University Mardan, Mardan, Pakistan.
  • Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia.
  • Department of Nephrology, Lady Reading Hospital Peshawar, Peshawar, Pakistan.
  • Department of Pharmacy, University of Peshawar, Peshawar, Pakistan.
  • Faculty of Data Science and Information Technology, INTI International University, Nilai, Malaysia.
  • School of Medical and Life Sciences, Sunway University, Bandar Sunway, Malaysia.

ORCID-Profile: Inayat Ur Rehman, Yasar Shah

Zitieren

APA

Gul, N., Rehman, I. U., Shah, Y., Ali, A. M., Ali, Z., Shehzad, O., Goh, K. W., Ming, L. C., & Suleiman, A. K. (2024). Comparing dual oral agents plus insulin vs. Triple oral agents in uncontrolled type II diabetes: A pilot study. PLOS ONE. https://doi.org/10.1371/journal.pone.0311435

Vancouver

Gul N, Rehman IU, Shah Y, Ali AM, Ali Z, Shehzad O, et al. Comparing dual oral agents plus insulin vs. Triple oral agents in uncontrolled type II diabetes: A pilot study. PLOS ONE. 2024. doi:10.1371/journal.pone.0311435

BibTeX
@article{Gul2024,
  author = {Gul, Nadia and Rehman, Inayat Ur and Shah, Yasar and Ali, Arbab Muhammad and Ali, Zahid and Shehzad, Omer and Goh, Khang Wen and Ming, Long Chiau and Suleiman, Amal K},
  title = {Comparing dual oral agents plus insulin vs. Triple oral agents in uncontrolled type II diabetes: A pilot study},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0311435}
}
Kostenlos starten →